KYNB Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Kyntra Bio Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerKYNB

Market Cap27.8M

Cash RunwayUnknown

Next Catalystn/a

Public Research Snapshot

Kyntra Bio Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Roxadustat in Hemodialysis Chronic Kidney Disease Patients With Anemia (Approved).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Roxadustat	Hemodialysis Chronic Kidney Disease Patients With Anemia	n/a	Approved	Public pipeline row
FG-3246	mCRPC and has the potential for additional trials targeting additional CD46-expressing cancers	Adc	Phase 2	Public pipeline row
ASP1517	Healthy Subjects	n/a	Phase 1	Public pipeline row
SEPO®	Chemotherapy Induced Anemia	n/a	Phase 3	Public pipeline row
Pamrevlumab	Idiopathic Pulmonary Fibrosis	n/a	Phase 3	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Unknown.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01244763	Phase 2	COMPLETED	145	2012-06-13
NCT01147666	Phase 2	COMPLETED	161	2012-10-15
NCT02805374	Phase 1	COMPLETED	16	2016-08
NCT02779764	Phase 3	COMPLETED	164	2017-05-16
NCT02780141	Phase 3	COMPLETED	75	2017-12-12
NCT02952092	Phase 3	COMPLETED	303	2018-03-13
NCT02964936	Phase 3	COMPLETED	100	2018-08-15
NCT05301517	Phase 3	COMPLETED	159	2023-04-03

Scientific Context

literature_publication | MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.
literature_publication | Lactic acid bacteria and endogenous ethanol mediate proton pump inhibitor-associated MASLD: a multicohort cross-sectional mediation analysis.
literature_publication | Bile salt hydrolase activity as a rational target for MASLD therapy.
literature_publication | Overcoming claudin family homology: discovery of ARC101, a highly potent CLDN6-specific T-cell engager with a novel CD3 binder for ovarian adenocarcinoma.
literature_publication | Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety.

Want the full KYNB research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.